Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Aurobindo Pharma USA Inc., (APUSA), a wholly owned subsidiary of Aurobindo Pharma, announced the successful completion of its acquisition of Lannett Company, Inc., USA (Lannett), from Lannett Seller Holdco, Inc., following receipt of approval from the U.S. Federal Trade Commission on 18 June 2026.
Effective 29 June 2026, Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC.
The integration process will commence immediately, with a strong emphasis on ensuring uninterrupted access to critical medications, maintaining trusted relationships with partners, and supporting employees throughout the transition.
The inspection concluded with two observations. The company said it will respond to the observations within the stipulated timeline.
Aurobindo Pharma reiterated its commitment to maintaining the highest quality manufacturing standards and said it will keep the stock exchanges informed of any further developments related to the inspection.
The official announcement was made on Saturday, 27 June 2026.
Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.
The counter advanced 1.15% to Rs 1,572.85 on the BSE.
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from 22 June 2026, to 26 June 2026.
The inspection concluded with 2 observations and will be responded to within the stipulated time.
The counter advanced 1.65% to end at Rs 1,554.95 on the BSE.
Aurobindo Pharma USA, Inc. (Aurobindo USA), a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett).
The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026.
Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances.
The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a U.S.-based manufacturing facility to its network.
Lannett's manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA's domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.
The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company's portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.
Lannett, a Pennsylvania-based generic pharmaceutical company, focuses on the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition is expected to significantly strengthen Aurobindo USA’s presence in this segment while adding a U.S.-based manufacturing facility to its operations.
The deal includes Lannett’s manufacturing facility in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA’s domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.
According to the company, the acquisition is expected to be immediately accretive to the Aurobindo Group’s earnings per share. It is also anticipated to generate cost efficiencies, SG&A synergies and operational integration benefits while expanding the company’s portfolio of complex generics and controlled substances, supporting long-term growth.
Swami S. Iyer, chief executive officer of Aurobindo Pharma USA, said, “This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion. We are pleased to welcome the Lannett team and look forward to leveraging our combined strengths to expand and ensure reliable access to critical medications for patients.”
Tim Crew, Lannett Company’s chief executive officer, said, “We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere. Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment. We look forward to building on all that has come before as we begin a bright and exciting next chapter.”
The counter shed 0.92% to Rs 1,484 on the BSE.
Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1479.9, up 2.51% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.88% on the day, quoting at 23954.5. The Sensex is at 76644.39, down 0.99%. Aurobindo Pharma Ltd has slipped around 2.48% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 1.61% in last one month and is currently quoting at 24282.2, up 0.66% on the day. The volume in the stock stood at 11.78 lakh shares today, compared to the daily average of 13.39 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1483.2, up 2.49% on the day. Aurobindo Pharma Ltd is up 34.88% in last one year as compared to a 4.61% drop in NIFTY and a 13.09% drop in the Nifty Pharma index.
The PE of the stock is 34.51 based on TTM earnings ending March 26.
At the conclusion of the inspection, the regulator had issued 11 observations to the facility. The company has now informed stock exchanges that the US FDA has determined the inspection classification status as OAI.